# A NEW METHOD OF RADIOLABELING ANTIBODY FOR TUMOR IMAGING

> **NIH NIH R01** · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 1989 · $161,024

## Abstract

We will expand our on-going investigations into the coupling and labeling
of proteins using the cyclic anhydride of DTPA and into the in vitro and in
vivo behavior of the proteins and the attached labels.

Specifically, we will study several attractive anti-tumor antibodies,
labeled with indium-111, in cancer patients to further establish the
pharmacokinetic and stability of the label and to assess this imaging
modelity for the detection of cancer.  These studies will be modeled after
our previous clinical investigation although we will include two additional
studies.  We will co-administer with the indium-111 labeled antibody, the
same antibody labeled at tracer levels with iodine-125.  Thereby we will
compare, in the same patient and for the same antibody, the behavior of
both labels.  In addition, we will use normal and tumor tissue obtained
from these patients at surgery in the in vitro antibody binding assay
developed in our laboratory to assess its value in predicting antibody
localization in patients.

We will also apply the cyclic anhydride labeling methodology to the
labeling of tissue plasminogen activator with indium-111.  Our initial
investigations of this labeled protein in vitro and in animals suggest that
it may be useful for the detection of forming clots.  It is possible that
this study may proceed quickly to clinical trials.

Other radionuclides besides indium-111 have attractive properties.  We will
continue to improve upon the labeling of antibodies with yttrium-90 towards
the eventual goal of preparing a product suitable for use in patients for
therapy.  Similarly, we will investigate gadolinium-153-labeled proteins to
establish whether label stability in serum is sufficient for NMR contrast
use.  We will also continue our studies into the labeling of proteins with
technetium-99m.  Besides labeling antibodies with this radionuclide, we
will label tissue plasminogen activator because of its rapid clot
localization and blood clearance.

Finally, we plan a number of in vitro investigations.  For example, we will
continue to use liver homogenates to determine the fate of indium and
iodine labeled antibodies.  We will investigate liver localization of
antibody modified in the carbohydrate region and we will investigate
aspects of protein chemistry such as the measurement of the immunoreactive
fraction after alterations in coupling procedure.

## Key facts

- **NIH application ID:** 3170962
- **Project number:** 5R01CA033029-07
- **Recipient organization:** UNIV OF MASSACHUSETTS MED SCH WORCESTER
- **SAM.gov UEI:** MQE2JHHJW9Q8
- **Principal Investigator:** DONALD J HNATOWICH
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $161,024
- **Award type:** 5
- **Project period:** 1983-05-01 → 1991-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3170962

## Citation

> US National Institutes of Health, RePORTER application 3170962, A NEW METHOD OF RADIOLABELING ANTIBODY FOR TUMOR IMAGING (5R01CA033029-07). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3170962. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*